All Updates

All Updates

icon
Filter
Product updates
Thermo Fisher Scientific receives CMA clearance for Olink acquisition
Precision Medicine
Jul 8, 2024
This week:
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
Precision Medicine
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
AI Drug Discovery
Yesterday
Partnerships
Beacon Therapeutics collaborates with Abeona Therapeutics for ophthalmic gene therapy development
Cell & Gene Therapy
Yesterday
Funding
Pan Cancer T raises EUR 4.25 million in seed extension funding for preclinical studies of PCT1:CO-STIM TCR T-cell therapy
Cell & Gene Therapy
Yesterday
Partnerships
Accelerated Biosciences and Pluristyx partner to create clinical-grade induced pluripotent stem cell lines
Cell & Gene Therapy
Yesterday
M&A
SoftBank acquires UK AI chipmaker Graphcore to improve AI capabilities
Edge Computing
Yesterday
Precision Medicine

Precision Medicine

Jul 8, 2024

Thermo Fisher Scientific receives CMA clearance for Olink acquisition

Product updates

  • Thermo Fisher Scientific has received clearance from Sweden's Competition and Markets Authority (CMA) for the acquisition of Olink Holding, valued at USD 3.1 billion. The clearance was given after the completion of CMA's investigations, which commenced in May 2024 after the initial inquiry.

  • Post-acquisition, Thermo Fisher Scientific will gain rights to Olink’s protein analysis assays, which can be run on laboratories’ installed qPCR instruments and next-generation sequencers. It will also gain rights to Olink's international operations, which are based in Boston, Tokyo, and Shanghai.

  • Analyst QuickTake: The initial offer for the acquisition was made on  October 17, 2023 ,  with the company agreeing to purchase all Olink’s outstanding Nasdaq shares for USD 26 per share. The offer was set to expire on April 30, 2024, and was postponed to July 08, 2024, after multiple extensions.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.